These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19219538)

  • 1. The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.
    Silber HE; Kjellsson MC; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):81-99. PubMed ID: 19219538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of actual significance levels for covariate effects in NONMEM.
    Wählby U; Jonsson EN; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):231-52. PubMed ID: 11468939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covariate detection in population pharmacokinetics using partially linear mixed effects models.
    Bonate PL
    Pharm Res; 2005 Apr; 22(4):541-9. PubMed ID: 15846461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of type I error rates for the statistical sub-model in NONMEM.
    Wählby U; Bouw MR; Jonsson EN; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):251-69. PubMed ID: 12449498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reduction in between subject variability is not mandatory for selecting a new covariate.
    Lagishetty CV; Vajjah P; Duffull SB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of type I error rates when modeling ordered categorical data in NONMEM.
    Wählby U; Matolcsi K; Karlsson MO; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Feb; 31(1):61-74. PubMed ID: 15346852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test.
    Xu XS; Yuan M; Yang H; Feng Y; Xu J; Pinheiro J
    AAPS J; 2017 Jan; 19(1):264-273. PubMed ID: 27761720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of pharmacokinetic studies for latent covariates.
    Lagishetty CV; Coulter CV; Duffull SB
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):87-97. PubMed ID: 22161222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches to handling pharmacodynamic baseline responses.
    Dansirikul C; Silber HE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):269-83. PubMed ID: 18446428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
    Bertrand J; Comets E; Laffont CM; Chenel M; Mentré F
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):317-39. PubMed ID: 19562469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derivation of various NONMEM estimation methods.
    Wang Y
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):575-93. PubMed ID: 17620001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.
    Baverel PG; Savic RM; Wilkins JJ; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):297-315. PubMed ID: 19572188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.
    Ribbing J; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):109-34. PubMed ID: 15379381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of different tests based on observations for external model evaluation of population analyses.
    Brendel K; Comets E; Laffont C; Mentré F
    J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):49-65. PubMed ID: 20033477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the nonparametric estimation method in NONMEM VI.
    Savic RM; Kjellsson MC; Karlsson MO
    Eur J Pharm Sci; 2009 Apr; 37(1):27-35. PubMed ID: 19159684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statistical evaluation of clinical trial design for a population pharmacokinetic study--a case study.
    Nakade S; Nishibori A; Okamoto H; Higuchi S
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):381-9. PubMed ID: 15548850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Modified Hybrid Wald's Approximation Method for Efficient Covariate Selection in Population Pharmacokinetic Analysis.
    Zou Y; Tang F; Ng CM
    AAPS J; 2021 Mar; 23(2):37. PubMed ID: 33660056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.
    Sherer EA; Sale ME; Pollock BG; Belani CP; Egorin MJ; Ivy PS; Lieberman JA; Manuck SB; Marder SR; Muldoon MF; Scher HI; Solit DB; Bies RR
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):393-414. PubMed ID: 22767341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.